Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Aug;105(2):103-115.
doi: 10.1111/ejh.13423. Epub 2020 May 27.

Factor VIII and IX assays for post-infusion monitoring in hemophilia patients: Guidelines from the French BIMHO group (GFHT)

Emmanuelle Jeanpierre  1 , Claire Pouplard  2 , Dominique Lasne  3 , Véronique Le Cam Duchez  4 , Valérie Eschwege  5 , Claire Flaujac  6 , Hubert Galinat  7 , Ines Harzallah  8 , Valérie Proulle  9 , Motalib Smahi  10 , Frédéric Sobas  11 , Nataliia Stepina  12 , Pierre Toulon  13 , Sophie Voisin  14 , Catherine Ternisien  15 , Christophe Nougier  11 ; French Study Group on the Biology of Hemorrhagic Diseases (the BIMHO group)
Collaborators, Affiliations
Review

Factor VIII and IX assays for post-infusion monitoring in hemophilia patients: Guidelines from the French BIMHO group (GFHT)

Emmanuelle Jeanpierre et al. Eur J Haematol. 2020 Aug.

Abstract

Replacement therapy with plasma-derived or recombinant FVIII and FIX (pdFVIII/pdFIX or rFVIII/rFIX) concentrates is the standard of treatment in patients with haemophilia A and B, respectively. Measurement of factor VIII (FVIII:C) or factor IX (FIX:C) levels can be done by one-stage clotting assay (OSA) or chromogenic substrate assay (CSA). The French study group on the Biology of Hemorrhagic Diseases (a collaborative group of the GFHT and MHEMO network) presents a literature review and proposals for the monitoring of FVIII:C and FIX:C levels in treated haemophilia A and B patients, respectively. The use of CSA is recommended for the monitoring of patients treated with pdFVIII or rFVIII including extended half-life (EHL) rFVIII. Except for rFVIII-Fc, great caution is required when measuring FVIII:C levels by OSA in patients substituted by EHL-rFVIII. The OSA is recommended for the monitoring of patients treated with pdFIX or rFIX. Large discordances in the FIX:C levels measured for extended half-life rFIX (EHL-rFIX), depending on the method and reagents used, must lead to great attention when OSA is used for measuring FIX:C levels in patients substituted by EHL-rFIX. Data of most of recent studies, obtained with spiked plasmas, deserve to be confirmed in plasma samples of treated patients.

Keywords: Factor IX; Factor VIII; chronometric and chromogenic assays; haemophilia A; haemophilia B.

PubMed Disclaimer

References

REFERENCES

    1. Caron C, Dautzenberg M-D, Delahousse B, et al. A blinded in vitro study with Refacto mock plasma samples: similar FVIII results between the chromogenic assay and a one-stage assay when using a higher cephalin dilution. Haemophilia. 2002;8:639-643.
    1. Dawson NJ, Kemball-Cook G, Barrowcliffe TW. Assay discrepancies with highly purified factor VIII concentrates. Haemostasis. 1989;19:131-137.
    1. Van den Bossche D, Peerlinck K, Jacquemin M. New challenges and best practices for the laboratory monitoring of factor VIII and factor IX replacement. Int J Lab Hematol. 2018;40:21-29.
    1. Hubbard AR, Dodt J, Lee T, et al. Recommendations on the potency labelling of factor VIII and factor IX concentrates. J Thromb Haemost. 2013;11:988-989.
    1. Barrowcliffe TW, Raut S, Sands D, Hubbard AR. Coagulation and chromogenic assays of factor VIII activity: general aspects, standardization, and recommendations. Semin Thromb Hemost. 2002;28:247-256.

MeSH terms

LinkOut - more resources